SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
暂无分享,去创建一个
Rommie E. Amaro | L. Casalino | R. Rappuoli | J. McLellan | R. Amaro | A. Manenti | E. Montomoli | D. Licastro | S. D. Monego | N. Johnson | G. Piccini | I. Paciello | Elisa Casa | I. Hyseni | Emanuele Andreano | Noemi Manganaro | Elisa Pantano | Linda Benincasa | Rachele Manna | Ida Paciello | Giulia Piccini
[1] Rommie E. Amaro,et al. The roles of glycans in the SARS-CoV-2 spike protein , 2022, Biophysical Journal.
[2] Sergei L. Kosakovsky Pond,et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa , 2020, medRxiv.
[3] Lei Huang,et al. AI-Driven Multiscale Simulations Illuminate Mechanisms of SARS-CoV-2 Spike Dynamics , 2020, bioRxiv.
[4] Gaurav D. Gaiha,et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.
[5] Min Zheng,et al. A systematic review of SARS-CoV-2 vaccine candidates , 2020, Signal Transduction and Targeted Therapy.
[6] G. Atwal,et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters , 2020, Science.
[7] Extremely potent human monoclonal antibodies from convalescent Covid-19 patients , 2020, bioRxiv.
[8] Rommie E. Amaro,et al. Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein , 2020, ACS central science.
[9] F. Krammer. SARS-CoV-2 vaccines in development , 2020, Nature.
[10] J. Sivaraman,et al. Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions , 2020, Trends in Immunology.
[11] Y. Wang,et al. The flexibility of ACE2 in the context of SARS-CoV-2 infection , 2020, bioRxiv.
[12] Benjamin P. Kellman,et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 , 2020, Cell.
[13] Sarah K. Hilton,et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition , 2020, bioRxiv.
[14] M. Catanzaro,et al. Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2 , 2020, Signal Transduction and Targeted Therapy.
[15] Ralf Bartenschlager,et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.
[16] S. Nakagawa,et al. Genome evolution of SARS-CoV-2 and its virological characteristics. , 2020, Inflammation and regeneration.
[17] J. Diedrich,et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate , 2020, bioRxiv.
[18] P. Rocchi,et al. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting , 2020, Molecular Cell.
[19] Yi Wang,et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. , 2020, The Journal of chemical physics.
[20] Nguyen H. Tran,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.
[21] Lisa E. Gralinski,et al. Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.
[22] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[23] Benjamin P. Kellman,et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 , 2020, bioRxiv.
[24] Qiang Zhou,et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.
[25] G. Atwal,et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies , 2020, Science.
[26] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[27] Rommie E. Amaro,et al. Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein , 2020, bioRxiv.
[28] Ilya J. Finkelstein,et al. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.
[29] A. Manenti,et al. Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples , 2020, Journal of medical virology.
[30] Daniel Wrapp,et al. Site-specific glycan analysis of the SARS-CoV-2 spike , 2020, Science.
[31] Asif Shajahan,et al. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 , 2020, Glycobiology.
[32] K. Yuen,et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.
[33] Asif Shajahan,et al. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 , 2020, bioRxiv.
[34] C. Hillyer,et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.
[35] Linqi Zhang,et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.
[36] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[37] Qiang Zhou,et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.
[38] Rommie E. Amaro,et al. Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit , 2019, mBio.
[39] Nico Pfeifer,et al. Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals , 2018, Nature Medicine.
[40] Alexis Rohou,et al. cisTEM: User-friendly software for single-particle image processing , 2017, bioRxiv.
[41] Yuelong Shu,et al. GISAID: Global initiative on sharing all influenza data – from vision to reality , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[42] David J. Fleet,et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.
[43] Stefan Elbe,et al. Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.
[44] B. L. de Groot,et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.
[45] W. Kong,et al. N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03 , 2015, Journal of acquired immune deficiency syndromes.
[46] Jing Huang,et al. CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data , 2013, J. Comput. Chem..
[47] J. Nie,et al. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization , 2013, Retrovirology.
[48] Jan H. Jensen,et al. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.
[49] Alexander D. MacKerell,et al. CHARMM Additive All-Atom Force Field for Glycosidic Linkages between Hexopyranoses. , 2009, Journal of chemical theory and computation.
[50] Bette Korber,et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.
[51] M Kundi,et al. One-hit models for virus inactivation studies. , 1999, Antiviral research.
[52] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[53] B. Brooks,et al. Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .
[54] M. Klein,et al. Constant pressure molecular dynamics algorithms , 1994 .
[55] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[56] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[57] D. Ermak,et al. Brownian dynamics with hydrodynamic interactions , 1978 .
[58] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .